News
IPHA
2.370
-2.27%
-0.055
Weekly Report: what happened at IPHA last week (0415-0419)?
Weekly Report · 1d ago
Buy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth Potential
TipRanks · 04/16 06:36
Weekly Report: what happened at IPHA last week (0408-0412)?
Weekly Report · 04/15 09:09
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
First patient dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 in acute myeloid leukemia. Innate Pharma and Sanofi are working together to develop innovative NK cell engagers to treat certain types of cancer. The first patient in the trial received FDA Fast Track Designation.
Barchart · 04/15 00:00
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Innate Pharma SA will hold its Annual General Meeting of Shareholders on May 23, 2024 in its headquarters in Marseille. The Notice of Meeting of this AGM was published on April 15, 2024. The Company will hold the AGM at 10:30 a.m. CEST.
Barchart · 04/15 00:00
Innate Pharma Price Target Maintained With a $11.50/Share by HC Wainwright & Co.
Dow Jones · 04/11 11:48
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Benzinga · 04/11 11:36
Innate Pharma: A Strong Buy on IPH45’s Promising Data and Solid Financial Projections
TipRanks · 04/11 10:27
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
NASDAQ · 04/10 16:00
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
First preclinical data for Innate Pharma's asset IPH45, a novel exatecan-Antibody Drug Conjugate (ADC) targeting Nectin-4, presented at the American Association for Cancer Research Annual Meeting 2024. In preclinical studies, data demonstrated that IPh45 effectively inhibits tumor growth. In non-clinical models, IPH 45 is well tolerated and shows anti-tumor efficacy.
Barchart · 04/10 00:00
Innate Pharma Announces Its Participation in Upcoming Investor Conference
Innate Pharma S.A. Is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Members of the company's executive team are scheduled to participate in the upcoming investor conference. Van Lanschot Kempen conference is scheduled for April 16-17, 2024 in Amsterdam, Netherlands.
Barchart · 04/09 00:00
Weekly Report: what happened at IPHA last week (0401-0405)?
Weekly Report · 04/08 09:09
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
Innate Pharma S.A. Is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. The company filed its 2023 Universal Registration Document for the year ending December 31, 2023 with the French market authority on April 4, 2024. The Company also announced today the filing of its annual report on Form 20-F with the U.S. Securities and Exchange Commission.
Barchart · 04/05 02:34
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. Kineta shares rose 8.46% and Simulations Plus shares increased by 6.74%. The company's market cap stands at $24.9 million.
Benzinga · 04/03 20:31
12 Health Care Stocks Moving In Monday's Pre-Market Session
Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0.23 during Monday's pre-market session. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock rose 14.76% in the pre- market session. Sunshine Biopharma ( NASDAQ:SBFM) shares also rose.
Benzinga · 04/01 12:08
Weekly Report: what happened at IPHA last week (0325-0329)?
Weekly Report · 04/01 09:09
Innate Pharma SA: A Balanced Hold Rating Amidst Clinical Setbacks and Cautious Optimism
TipRanks · 03/26 20:45
Weekly Report: what happened at IPHA last week (0318-0322)?
Weekly Report · 03/25 09:09
Innate Pharma Price Target Maintained With a $11.50/Share by HC Wainwright & Co.
Dow Jones · 03/22 10:32
Innate Pharma: A Strong Buy on Promising Clinical Progress and Solid Financials
TipRanks · 03/22 10:27
More
Webull provides a variety of real-time IPHA stock news. You can receive the latest news about Innate Pharma Sa through multiple platforms. This information may help you make smarter investment decisions.
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.